Physiology Core

生理学核心(C.Rosen，核心总监) 生理学核心的长期目标是提供高质量的体内和体外代谢表型 为Cobre项目、其他MaineHealth研究人员和外部调查人员提供服务。第一阶段 取得的成就包括通过收购8 G2扩大和升级我们的代谢表型 HR E-Mitter遥测系统、海马XF96分析仪、Cytation I细胞成像仪、Faxitron UltraFocus DXA X光机和Sable Systems呼吸测量跑步机，基于我们用户的需求。我们成功地 支持我们的Cobre调查人员和非Cobre机构的教职员工、研究人员和受训人员，从而 满足我们的目标指标，以支持资助拨款申请和出版物。在过去五年中， 所有四个最初的项目负责人都得到了独立的R01资助，并且经常使用生理学 核心，用于实验服务或咨询罗森博士。他们的研究包括对细胞的分析 生物能量学、身体成分、代谢和行为研究。此外，我们还成功地 通过与新英格兰大学索拉亚生物分校的合作项目提高外部利用率 (马萨诸塞州剑桥)，Mt.西奈医学院、塔夫茨大学和康奈尔大学。这些都导致了稳定的 增加年度服务费收入，这对可持续发展是不可或缺的。生理学核心的使用是 帮助资助NIA向Zaidi博士(Mt.和Rosen(生理学核心 董事)。发表在PNAS，J生物化学，J临床研究和JCI Insight，eLife，癌症研究， 《细胞新陈代谢》、《自然通讯》和《细胞报告》都是这个核心实验的直接结果。 重要的是，生理学核心支持年轻的研究人员接受培训，包括成功的 为F31和F32提供资金。大多数试点项目获奖者使用了该核心的一个功能，以及 向本科生提供与核心设备新技术方面相关的教育课程 以及研究生和博士后研究员。第二阶段为生理学提供了新的机遇 在新技术、更广泛地使用现有设备和更多的培训机会方面发挥核心作用。在……里面 此外，我们最近获得了Cobre设备补充，以扩大新陈代谢的数量 笼子，并在系统内集成一个温控孵化器。因此，在第二阶段，我们扩大了 我们的设备和能力，以满足代谢和行为表型的高需求，并将 为热中性和低温下的活体研究提供新的服务。我们将维持我们的 高利用率的高级细胞和线粒体生物能量分析服务，除了提供 在研究研究设计和实施以及数据分析方面提供专家协助。成功的领导层， 该核心的管理和运作原则将保持不变，并为项目提供科学支持 领导莱恩斯、李和阿加瓦尔博士，以及其他MaineHealth和外部调查人员。

Physiology Core (C. Rosen, Core Director) The long-term goal of the Physiology Core is to provide high quality in vivo and in vitro metabolic phenotyping services for COBRE projects, other MaineHealth researchers, and outside investigators. Phase I accomplishments include expanding and upgrading our metabolic phenotyping through the acquisition of 8 G2 HR E-Mitter telemetry systems, a Seahorse XF96 analyzer, a Cytation I cell imager, a Faxitron UltraFocus DXA X-ray machine and a Sable Systems respirometry treadmill, based on our users’ needs. We successfully supported our COBRE investigators and non-COBRE institutional faculty, research staff, and trainees, thereby meeting our targeted metrics for support of funded grant applications and publications. Over the last five years, all four original project leads received independent R01 funding, and were frequent users of the Physiology Core, for experimental services or consultation with Dr. Rosen. Their studies included analysis of cellular bioenergetics, body composition, and metabolic and behavioral studies. Moreover, we have successfully increased outside utilization through collaborative projects with the University of New England, Solarea Bio (Cambridge, MA), Mt. Sinai School of Medicine, Tufts and Cornell Universities. These resulted in steady increases in annual service fee revenue that is integral for sustainability. Use of the Physiology Core was instrumental in the funding of a multi-PI U19 from NIA to Drs. Zaidi (Mt. Sinai) and Rosen (Physiology Core Director). Publications in PNAS, J Biol Chem, J Clinical Investigation and JCI Insight, eLife, Cancer Research, Cell Metabolism, Nature Communications, and Cell Reports were direct results of experiments from this Core. Importantly, the Physiology Core was supportive of young investigators in training, including the successful funding of an F31 and an F32. Most of the pilot project awardees used one of the features of this Core, and educational programs related to new technical aspects for Core equipment were provided to undergraduate and graduate students as well as postdoctoral fellows. Phase II offers new opportunities for the Physiology Core in respect to novel technologies, expanded use of current equipment and greater training opportunities. In addition, we were recently awarded a COBRE equipment supplement to expand the number of metabolic cages and integrate a temperature-controlled incubator within the system. Thus in Phase II, we have expanded our equipment and capacity to meet the high demand for metabolic and behavioral phenotyping, and will also provide new services for in vivo studies at thermoneutrality and at cold temperatures. We will maintain our highly utilized services for advanced cellular and mitochondrial bioenergetic analysis, in addition to providing expert assistance in research study design and implementation and data analysis. The successful leadership, management, and operational principles of this Core will remain in place, and scientifically support the project leads Drs. Lynes, Li, and Agarwal, and other MaineHealth and external investigators.